A Phase 4 interventional study of Enoxaparin (LMWH) and Dextrose Water in Oligohydramnios, Heparin and Neonatal Outcomes, sponsored by PAEC General Hospital, Islamabad. Recruiting at 1 site in Pakistan. Open to female participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by PAEC General Hospital, Islamabad · Phase 4, Interventional, and Treatment
The pregnant women who meet the study requirements will be included in the study. They will be randomly assigned to receive either the usual treatment or the usual treatment along with an additional medicine.
The usual treatment will include fluids given through a vein, rest while lying on the left side, and a low-dose aspirin tablet (75 mg once daily) from the 22nd to the 34th week of pregnancy. Women will also receive 1,000 ml of 5% dextrose fluid daily through a vein, from the time low amniotic fluid is diagnosed until the 36th week of pregnancy.
Some women will also receive an additional injection of a blood-thinning medicine called low-molecular-weight heparin (LMWH), at a dose of 40 mg under the skin, from the 22nd to the 36th week of pregnancy.
All participants will undergo weekly ultrasound examinations to measure the fluid surrounding the baby and assess blood flow through the umbilical cord. The study will record the number of babies born before 37 weeks of pregnancy, the babies' birth weights, and the number of babies born alive.
Study Methodology
Pregnant women meeting the eligibility criteria will be enrolled following ethical approval and randomly assigned to receive either conventional treatment alone or conventional treatment in combination with low-molecular-weight heparin (LMWH).
Conventional treatment will consist of left lateral positional rest, intravenous administration of 1,000 mL of 5% dextrose solution daily from the diagnosis of isolated oligohydramnios until 36 weeks of gestation, and oral aspirin at a dose of 75 mg once daily from 22 to 34 weeks of gestation.
In addition to conventional treatment, participants assigned to the intervention will receive subcutaneous LMWH at a dose of 40 mg from 22 to 36 weeks of gestation.
All participants will undergo weekly ultrasonographic assessment of the amniotic fluid index (AFI) and umbilical artery Doppler studies. The primary study outcomes will include the incidence of preterm birth before 37 completed weeks of gestation, neonatal birth weight, and live birth rate.
Clarify the Randomization and Treatment Groups Separate Primary and Secondary Outcomes
25 studies on the registry are indexed under Oligohydramnios; 5 are open to participants now.
This study's planned enrollment of 106 is above the median of 91 across 16 interventional studies indexed under Oligohydramnios.
Browse Oligohydramnios studies →PAEC General Hospital, Islamabad is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Enoxaparin (LMWH)
Drug: Dextrose Water
Participants will receive conventional treatment, including left lateral positional rest, intravenous 1,000 mL of 5% dextrose daily until 36 weeks of gestation, and oral aspirin 75 mg once daily from 22 to 34 weeks. Additionally, subcutaneous low-molecular-weight heparin (LMWH) 40 mg will be administered from 22 to 36 weeks of gestation.
Participants will receive conventional treatment, including left lateral positional rest, intravenous 1,000 mL of 5% dextrose daily until 36 weeks of gestation, and oral aspirin 75 mg once daily from 22 to 34 weeks of gestation, without LMWH.
Live birth rate
Time frame: At the time of delivery.
Incidence of Preterm Birth
Time frame: At the time of delivery.
Mean Birth weight
Time frame: At the time of delivery.
Plan to share: No — Hospital Ethical Committee doesn't allow IPD sharing
Started Oct 2026 (actual). Primary completion is estimated for Jan 2027, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enoxaparin
PAEC General Hospital, Islamabad